Page last updated: 2024-10-26

1-phenyl-2-palmitoylamino-3-morpholino-1-propanol and Precursor Cell Lymphoblastic Leukemia-Lymphoma

1-phenyl-2-palmitoylamino-3-morpholino-1-propanol has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 1 studies

1-phenyl-2-palmitoylamino-3-morpholino-1-propanol: a sphingolipid analog; inhibits the enzyme activity in infected erythrocytes
N-[1-hydroxy-3-(morpholin-4-yl)-1-phenylpropan-2-yl]hexadecanamide : A fatty amide resulting from the formal condensation of palmitic acid with the primary amino group of 2-amino-3-(morpholin-4-yl)-1-phenylpropan-1-ol.

Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
O'Donnell, PH1
Guo, WX1
Reynolds, CP1
Maurer, BJ1

Other Studies

1 other study available for 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol and Precursor Cell Lymphoblastic Leukemia-Lymphoma

ArticleYear
N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.
    Leukemia, 2002, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Cell Survival; Ceramides; Dose-Response Relationship, Drug; Drug Synergism; F

2002